Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 40 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Panidis, Dimitrios  [Clear All Filters]
2013
Panidis, D., Tziomalos K., Macut D., Kandaraki E. A., Tsourdi E. A., Papadakis E., et al. (2013).  Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome.. Gynecol Endocrinol. 29(10), 926-30.
Panidis, D., Tziomalos K., Chatzis P., Papadakis E., Delkos D., Tsourdi E. A., et al. (2013).  Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome.. Eur J Endocrinol. 168(2), 145-52.
Panidis, D., Tziomalos K., Papadakis E., Chatzis P., Kandaraki E. A., Tsourdi E. A., et al. (2013).  The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome.. Eur J Endocrinol. 168(6), 871-7.
Tziomalos, K., Katsikis I., Papadakis E., Kandaraki E. A., Macut D., & Panidis D. (2013).  Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.. Hum Reprod. 28(3), 785-93.
Vosnakis, C., Georgopoulos N. A., Rousso D., Mavromatidis G., Katsikis I., Roupas N. D., et al. (2013).  Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS).. Gynecol Endocrinol. 29(3), 242-5.
Koiou, E., Tziomalos K., Katsikis I., Delkos D., Tsourdi E. A., & Panidis D. (2013).  Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.. Hormones (Athens). 12(4), 559-66.
Panidis, D., Tziomalos K., Papadakis E., Kandaraki E. A., & Katsikis I. (2013).  The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require r. Hormones (Athens). 12(2), 192-200.
Panidis, D., Tziomalos K., Papadakis E., Vosnakis C., Chatzis P., & Katsikis I. (2013).  Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.. Endocrine. 44(3), 583-90.
Koiou, E., Tziomalos K., Katsikis I., Papadakis E., Kandaraki E. A., & Panidis D. (2013).  Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome.. Gynecol Endocrinol. 29(3), 250-3.
Panidis, D., Macut D., Tziomalos K., Papadakis E., Mikhailidis K., Kandaraki E. A., et al. (2013).  Prevalence of metabolic syndrome in women with polycystic ovary syndrome.. Clin Endocrinol (Oxf). 78(4), 586-92.
2012
Spanos, N., Tziomalos K., Macut D., Koiou E., Kandaraki E. A., Delkos D., et al. (2012).  Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss.. Obes Facts. 5(4), 495-504.
Panidis, D., Tziomalos K., Macut D., Delkos D., Betsas G., Misichronis G., et al. (2012).  Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.. Fertil Steril. 97(2), 494-500.
Panidis, D., Tziomalos K., Misichronis G., Papadakis E., Betsas G., Katsikis I., et al. (2012).  Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.. Hum Reprod. 27(2), 541-9.
Koiou, E., Tziomalos K., Dinas K., Katsikis I., Kandaraki E. A., Tsourdi E., et al. (2012).  Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.. Endocr J. 59(1), 21-9.
Koiou, E., Tziomalos K., Katsikis I., Dinas K., Tsourdi E. A., Kandaraki E. A., et al. (2012).  Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome.. Hormones (Athens). 11(1), 77-85.
Vosnakis, C., Georgopoulos N. A., Armeni A. K., Papadakis E., Roupas N. D., Katsikis I., et al. (2012).  Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.. Eur J Obstet Gynecol Reprod Biol. 163(2), 185-9.
Koiou, E., Tziomalos K., Katsikis I., Kandaraki E. A., Kalaitzakis E., Delkos D., et al. (2012).  Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.. Gynecol Endocrinol. 28(1), 20-4.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.